Search Results
Your search for ,USE matches 11181 pages
Showing 5001 - 5050Single Nucleotide Polymorphisms and Survival After Pancreatic Cancer Resection
In a study reported in JAMA Surgery, Dimitrakopoulos et al found two single nucleotide polymorphisms (SNPs) in noncoding, functional regions of genes that regulate cancer progression. They were associated with survival after resection of pancreatic ductal adenocarcinoma. The study involved...
ASTRO Radiation Oncologist Workforce Study Shows Demographic Shifts
The newest study of America’s radiation oncologist workforce finds that gender and racial gaps have narrowed slightly, although persistent and growing geographic disparities point to a need for more equity in access to radiation therapy care. The survey found that fewer radiation oncologists...
American Cancer Society Report Finds Application of Cancer-Reducing Strategies in the United States Is Suboptimal
The latest edition of the American Cancer Society’s (ACS) review on recent cancer prevention and early detection efforts has found that although many strategies have been proven to reduce cancer risk, their application has been suboptimal in the United States, especially in socioeconomically...
FDA Grants Accelerated Approval to Erdafitinib for Metastatic Urothelial Carcinoma
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to erdafitinib (Balversa) for patients with locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations that has progressed during or following platinum-containing...
Prophylactic Irradiation of Chest Wall Procedure Sites in Malignant Pleural Mesothelioma
In a phase III trial reported in the Journal of Clinical Oncology, Bayman et al found that prophylactic radiotherapy to the chest wall after diagnostic or therapeutic procedures did not reduce the risk of chest wall metastases in patients with malignant pleural mesothelioma. In the open-label,...
Opioid-Related Hospitalizations Among Patients With Cancer in the United States
In a study reported in a research letter in JAMA Oncology, Chua et al found that opioid-related hospitalizations among American patients with cancer are rare, increasing at a very low rate, and consist mostly of hospitalization for nonheroin opioid poisoning. The study analyzed trends and risk...
ELCC 2019: Immunotherapy in Elderly Patients With Advanced NSCLC
Two studies reported at the European Lung Cancer Congress (ELCC) 2019 provided new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non–small cell lung cancer (NSCLC). Although around half of all people newly diagnosed with NSCLC are elderly (Pallis ...
Initiative to Improve Tobacco Cessation Efforts in a Radiation Oncology Department
In a study reported in the Journal of Oncology Practice, Singer et al found that a quality improvement initiative was successful in increasing a radiation oncology department’s efforts in encouraging patients with cancer to cease tobacco use prior to radiation therapy. As noted by the...
ASCO Seeks Applicants for Research Grants to Use Data From CancerLinQ Discovery
ASCO recently announced that it is seeking applications for research grants for projects that use data from CancerLinQ Discovery®—an offering of ASCO’s CancerLinQ® initiative—as a source. CancerLinQ Discovery provides curated sets of deidentified data from patients with cancer to academic...
Better Techniques Coming to Breast Cancer Screening
BREAST CANCER SCREENING is no longer “just mammography” but involves a growing list of ever more sophisticated techniques that are improving detection, according to Elizabeth Morris, MD, Professor of Radiology, the Larry Norton Chair, and Chief of the Breast Imaging Service at Memorial Sloan...
Maitake Mushroom
GUEST EDITOR Integrative Oncology is guest edited by Jun J. Mao, MD, MSCE, Laurance S. Rockefeller Chair in Integrative Medicine and Chief of Integrative Medicine Service at Memorial Sloan Kettering Cancer Center, New York. The ASCO Post’s Integrative Oncology series is intended to...
Human Gene Therapy: Progress and Oversight
The early debate over the social and ethical implications of gene therapy led the National Institutes of Health (NIH) to establish the Recombinant DNA Advisory Committee in 1974. However, the risks of human gene therapies were largely unknown until 1999, when a patient died of a massive immune...
Opioid Toolkit: Helping Nebraskan Hospitals to Provide Appropriate Pain Management
As the opioid epidemic continues to sweep the United States, providers across Nebraska are facing the challenge of determining the appropriateness of pain treatment options that both meet the needs of the patients and fall within nationally published guidelines. A recent report published by the...
Advanced HER2-Positive Breast Cancer: All Eyes on These Novel Agents
NEW AGENTS for the treatment of advanced HER2-positive breast cancer should be coming soon to your clinic, according to Sara A. Hurvitz, MD, Director of the Breast Cancer Clinical Research Program and Associate Professor of Medicine at the David Geffen School of Medicine at the University of...
FDA Warning: Investigational Use of Venetoclax in Multiple Myeloma
On March 21, 2019, the U.S. Food and Drug Administration (FDA) posted a safety statement on the investigational use of venetoclax in multiple myeloma. The statement alerts health-care professionals and patients about the suspension of the BELLINI trial (ClinicalTrials.gov identifier NCT02755597) of ...
Expert Point of View: Christopher L. Hallemeier, MD, and Andrew S. Kennedy, MD
Christopher L. Hallemeier, MD, Associate Professor in Radiation Oncology at the Mayo Clinic, Rochester, and Andrew S. Kennedy, MD, Physician in Chief of Radiation Oncology at Sarah Cannon, Nashville, and Director of Radiation Oncology Research, Sarah Cannon Research Institute, commented on the...
Expert Point of View: Tracy Rose, MD, MPH
THE FORMAL DISCUSSANT of the KEYNOTE-427 trial, Tracy Rose, MD, MPH, of the University of North Carolina, Chapel Hill, told listeners: “I think pembrolizumab should now be considered an option for non–clear cell kidney cancer. Response rates, however, remain inferior to those seen in clear cell...
Enzalutamide Plus ADT Extends Progression-Free Survival in Metastatic Hormone-Sensitive Prostate Cancer
Adding enzalutamide to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer, reducing the risk of disease progression or death by 61% compared with ADT plus placebo, according to the results of the ...
CDC Issues Clarification on Guideline for Prescribing Opioids for Chronic Pain in Patients With Cancer and Sickle Cell Disease
ASCO, the American Society of Hematology (ASH), and the National Comprehensive Cancer Network® (NCCN®) are pleased to acknowledge receipt of a key clarification from the Centers for Disease Control and Prevention (CDC) on prescribing opioids to manage pain from certain conditions. ...
Effect of Increased VA Hospice Care on Use of Aggressive Care and Costs for Veterans With Advanced Lung Cancer
In a study reported in JAMA Oncology, Mor et al found that veterans with advanced lung cancer treated in Veterans Affairs (VA) Medical Centers with high hospice use were more likely to receive concurrent cancer care but less likely to receive aggressive care. Moreover, veterans treated at...
Capecitabine vs Observation Following Surgery for Resected Biliary Tract Cancer
Watch John Marshall, MD, and BILCAP first author John Neil Primrose, PhD, MBBS, discuss the trial at the 2017 ASCO Annual Meeting. In the phase III BILCAP trial reported in The Lancet Oncology, Primrose and colleagues found evidence that adjuvant capecitabine may improve overall...
SBRT vs Conventionally Fractionated, or Moderately Hypofractionated External-Beam Radiotherapy, for Localized Prostate Cancer
TREATMENT WITH stereotactic body radiation therapy (SBRT) results in a similar safety profile to conventionally fractionated, or moderately hypofractionated external-beam radiotherapy, in men with low- or intermediate- risk prostate cancer, according to preliminary results of the Prostate Advances ...
Interim Analysis of the ARCHES Trial: Enzalutamide Plus Androgen-Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer
ADDING ENZALUTAMIDE to androgen-deprivation therapy (ADT) significantly prolonged radiographic progression-free survival in men with metastatic hormone-sensitive prostate cancer, reducing the risk of progression or death by 61% compared with ADT plus placebo, according to results of the phase III...
Preventive Medication Use in the Last Year of Life in Older Patients With Cancer
A new study reveals that preventive medications—such as those to lower blood pressure or cholesterol, or to protect bone health, among others—are commonly prescribed during the last year of life of older adults with cancer, even though they are unlikely to provide meaningful benefits....
Final Overall Survival Results With Fulvestrant Plus Anastrozole in Metastatic Breast Cancer
As reported in The New England Journal of Medicine by Mehta et al, the final overall survival results of the phase III SWOG S0226 trial show that the addition of first-line fulvestrant to anastrozole was associated with improved overall survival in postmenopausal women with hormone...
FDA Expands Palbociclib Indication in HR-Positive, HER2-Negative Breast Cancer to Include Male Patients
Today, the U.S. Food and Drug Administration (FDA) extended the indication of palbociclib (Ibrance) capsules in combination with specific endocrine therapies for hormone receptor (HR)–positive, HER2-negative advanced or metastatic breast cancer to include male patients. “Today, we are...
AACR 2019: Does Use of Oral Contraceptives Decrease the Risk of Fatal Ovarian Cancer?
Researchers have observed for several years that people who have a history of using oral contraceptives are less likely to develop ovarian cancer. A team from Roswell Park Comprehensive Cancer Center and the University at Buffalo analyzed those connections more deeply, reporting that the protective ...
Differences in Medical Cannabis Use in Patients With and Without Cancer
People with and without cancer are more likely, over time, to use a more potent form of medical marijuana with increasingly higher amounts of tetrahydrocannabinol (THC), a new study published by Kim et al in the Journal of Palliative Medicine has shown. “Although there is growing...
AACR 2019: Effect of Timing of Radiotherapy on Mucositis in Patients With Head and Neck Cancer
New research presented by Gu et al at the American Association for Cancer Research (AACR) Annual Meeting 2019 found that administering radiation treatments in the morning as opposed to later in the day may significantly reduce the severity of mucositis and its related impacts (Abstract 4860). ...
Racial Disparities in Matched Volunteer Stem Cell Donors
Although the pool of registered bone marrow donors has increased in recent years, a new study suggests that most patients of southern European and non-European descent are unlikely to have a suitable match if they need a bone marrow transplant. If an immediate registry search does not identify a...
Geriatric Assessment, Hospitalization, and Long-Term Care Use in Older Cancer Survivors
In a study reported in the Journal of Oncology Practice, Williams et al found that items in geriatric assessment were significantly predictive of hospitalization frequency and long-term care use among older cancer survivors. Study Details The study included 125 patients aged ≥ 65 years from...
FDA Oncology Center of Excellence Issues Annual Report
The U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) has issued its 2018 Annual Report, including updates on regulatory reviews and initiatives, OCE programs, guidances, and more. Regulatory Reviews The OCE is tasked with clinical medical oncology reviews, irrespective...
FDA Pipeline: Mammography Policies, Designations for Leukemias and Myelodysplastic Syndrome
This week, the U.S. Food and Drug Administration (FDA) announced policy changes to modernize mammography policies and issued a Breakthrough Therapy designation, an Orphan Drug designation, and an investigational new drug application. FDA Advances Policy Changes to Modernize Mammography Services...
ASCO Weighs in on Widespread Youth Tobacco Use: See the Latest National Youth Tobacco Survey Results
APPROXIMATELY 5 MILLION middle and high school students reported currently using a tobacco product, with over 3.6 million currently using e-cigarettes and about 2.5 million currently using a combustible tobacco product, according to the latest findings from the National Youth Tobacco Survey ...
Urge Congress to Support Medicaid Coverage of Routine Care Costs for Clinical Trials
MEMBERS OF CONGRESS recently reintroduced bipartisan legislation, the ‘Covering Life-Saving Investigations Needed in Cancer and Other Life-Threatening Conditions Through Timely Use of Resources for Easy and Affordable Treatment from Medicaid for Enrollees in Need Today Act,’ or the CLINICAL...
Conquer Cancer Honors Researchers With Merit Awards
ASCO’S CONQUER CANCER FOUNDATION is pleased to announce the recipients of the Gastrointestinal Cancers, Genitourinary Cancers, and Clinical Immuno-Oncology Symposium Merit Awards. Conquer Cancer Merit Awards recognize oncology fellows’ and trainees’ high-quality research submitted in abstracts to...
ASCO Endorses Active Surveillance Guideline for Low-Risk Prostate Cancer
ASCO ENDORSES and reinforces the evidence-based American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) Guideline published in 2018 in the Journal of Urology. ASCO’s endorsement of a guideline on clinically localized...
Prostatectomy vs Watchful Waiting: Clinical Dilemma Centers on Aggressive vs Indolent Disease
THE MANAGEMENT of localized prostate cancer remains controversial. Although the widespread use of prostate-specific antigen (PSA) testing has resulted in a dramatic increase in the diagnosis and treatment of prostate cancer, many men do not benefit from intervention because the disease is either...
Expert Point of View: Kenneth Shain, MD, PhD
KENNETH SHAIN, MD, PhD, Director of the Myeloma Working Group at Moffitt Cancer Center, Tampa, Florida, told The ASCO Post that ixazomib is “an effective drug,” but he is not ready to use it as maintenance therapy. He noted that the TOURMALINE-MM3 trial did meet its primary endpoint—but not...
Maintenance Ixazomib Delays Disease Progression in Newly Diagnosed Myeloma
IN PATIENTS with newly diagnosed multiple myeloma who responded well to induction therapy and underwent transplant, 2 years of maintenance therapy with ixazomib led to a 38% improvement in progression-free survival compared with placebo, according to the results of the phase III TOURMALINE-MM3...
Expert Point of View: Ajay K. Nooka, MD, MPH
THE ASCO POST asked Ajay K. Nooka, MD, MPH, Associate Professor, Division of Bone Marrow Transplant at Winship Cancer Institute, Emory University, to comment on studies involving daratumumab. “After the phase III SWOG S0777 trial demonstrated a survival benefit with a 3-drug induction regimen...
ASH Reports Show Benefit of Adding Daratumumab to Initial Therapy in Multiple Myeloma
DARATUMUMAB APPEARS to be the “gift that keeps on giving” to the myeloma community. “It seems we can add daratumumab to almost anything and make the regimen better. It’s got good activity and a good safety profile,” said Kenneth Shain, MD, PhD, Director of the Myeloma Working Group at Moffitt...
IMpassion130 Substudy: Atezolizumab/Nab-Paclitaxel Survival Benefits Limited to PD-L1–Positive Triple-Negative Breast Cancer
THE PHASE III IMpassion130 trial, first reported at the European Society for Medical Oncology (ESMO) 2018 Congress1 and published in The New England Journal of Medicine,2 found that the combination of front-line atezolizumab plus nab-paclitaxel significantly improved disease-free and overall...
New ASCO Guideline on Head and Neck Cancer Clarifies Lymph Node Management
A NEW ASCO guideline, “Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline,” aims to clarify issues in lymph node management.1 “This guideline represents a true multidisciplinary synthesis of some important new information about...
FDA Commissioner Scott Gottlieb, MD, Resigns
ON MARCH 5, 2019, Scott Gottlieb, MD, announced his resignation as Commissioner of the U.S. Food and Drug Administration (FDA), a post he began in 2017. Dr. Gottlieb’s resignation will be effective in April. In a resignation letter to Alex M. Azar II, Secretary of Health and Human Services (HHS),...
Antibiotic Treatment Prior to Immune Checkpoint Inhibitor Therapy Shows Detrimental Effect on Response and Survival
USE OF ANTIBIOTICS prior to checkpoint blockade therapy may attenuate anticancer activity, according to data presented at the 2019 ASCO–Society for Immunotherapy of Cancer (SITC) Clinical Immuno-Oncology Symposium.1 Results of the multicenter study suggest that antibiotic therapy administered...
PARP Inhibitors Moving Ahead in Prostate Cancer
MULTIPLE POLY (ADP-ribose) polymerase (PARP) inhibitors are under study in metastatic prostate cancer and no clear winner has emerged yet. Some studies suggest that the best use of PARP inhibitors may be in patients whose cancers harbor DNA-repair defects and BRCA1/2 mutations, but other data...
Trastuzumab Biosimilar for HER2-Overexpressing Breast Cancer
ON DECEMBER 14, 2018, trastuzumab-pkrb (Herzuma) was approved as a biosimilar to trastuzumab for patients with HER2-overexpressing breast cancer.1 Trastuzumab-pkrb is indicated for adjuvant treatment of HER2-overexpressing breast cancer and metastatic HER2-overexpressing breast cancer.2 Health-care ...
New Data in Colorectal, Neuroendocrine, Gastric, and Hepatocellular Cancers
THE ANNUAL GASTROINTESTINAL CANCERS SYMPOSIUM took place earlier this year in San Francisco. In addition to important studies captured in our past few issues, The ASCO Post here briefly summarizes additional interesting studies. Adjuvant Hyperthermic Intraperitoneal Chemotherapy in Colon Cancer...
CheckMate 384 Supports More Convenient Dosing of Nivolumab in Advanced NSCLC
PATIENTS WITH advanced non–small cell lung cancer (NSCLC) may no longer have to come to the clinic every 2 weeks for treatment. According to a descriptive analysis of the phase IIIb/IV CheckMate 384 study, a more convenient dosing option of nivolumab has demonstrated convincing short-term safety...
